Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Postmarketing Study Status Reports Need Sponsor Pre-Clearance - PhRMA

This article was originally published in The Tan Sheet

Executive Summary

Portions of postmarketing study annual status reports that will be publicly disclosed should be pre-specified by study sponsors, the Pharmaceutical Research & Manufacturers of America suggests to FDA in Feb. 14 comments.

You may also be interested in...

Postmarketing Study's "End Of Usefulness" Must Be Confirmed By FDA

Industry must continue to submit status reports on terminated postmarketing drug studies until FDA concurs the studies will provide no more useful information under a proposed revision to postmarketing study status annual reporting regs published in the Dec. 1 Federal Register.

Advisory Committee Topics Will Narrow In Response To HRG Suit - FDA

FDA will ask more directed questions of its advisory committees as a way to narrow the amount of information from NDAs provided to the committees, FDA's Office of Training and Communications Director Nancy Smith, PhD, told the recent Regulatory Affairs Professionals Society annual meeting in Washington, D.C.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts